|
1) Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006; 108: 2509
|
|
|
|
2) 中尾眞二, 浦部晶夫, 別所正美, 他. 再生不良性貧血診療の参照ガイド. 臨床血液. 2005; 47: 27-46
|
|
|
|
|
3) Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009; 114: 2236-43
|
|
|
|
|
|
4) Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008; 154: 502-21
|
|
|
|
|
|
5) Hengge UR, Stocks K, Wiehler H, et al. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting. AIDS. 2003; 17: 699-710
|
|
|
|
|
|
6) Rencricca NJ, Solomon J, Fimian WJ Jr, et al. The effect of testosterone on erythropoiesis. Scand J Haematol. 1969; 6: 431-6
|
|
|
|
|
|
7) Francis GE, Berney JJ, Bateman SM, et al. The effect of androstanes on granulopoiesis in vitro and in vivo. Br J Haematol. 1977; 36: 501-10
|
|
|
|
|
|
8) Araneo BA, Dowell T, Diegel M, et al. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4(IL-4), IL-5, and gamma-interferon, but not IL-2 by activated murine T cells. Blood. 1991; 78: 688-99
|
|
|
|
|
|
9) Gardner FH. Androgen therapy of aplastic anaemia. Clin Haematol. 1978; 7: 571-85
|
|
|
|
|
|
10) Sanchez-Medal L, Gomez-Leal A, Duarte L, et al. Anabolic androgenic steroids in the treatment of acquired aplastic anemia. Blood. 1969; 34: 283-300
|
|
|
|
|
|
11) OʼSullivan RJ, Karlseder J. Telomeres: protecting chromosomes against genome instability. Nat Rev Mol Cell Biol. 2010; 11: 171-81
|
|
|
|
|
|
12) Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990; 345: 458-60
|
|
|
|
|
|
13) Harley CB, Vaziri H, Counter CM. The telomere hypothesis of cellular aging. Exp Gerontol. 1992; 27: 375-82
|
|
|
|
|
|
14) 山口博樹, 檀 和夫. テロメア関連遺伝子異常による骨髄不全症. 臨床血液. 2010; in press
|
|
|
|
|
|
15) Walne AJ, Dokal I. Advances in the understanding of dyskeratosis congenita. Br J Haematol. 2009; 145: 164-72
|
|
|
|
|
|
16) Brummendorf TH, Maciejewski JP, Mak J, et al. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001; 97: 895-900
|
|
|
|
|
|
17) Bayne S, Liu JP. Hormones and growth factors regulate telomerase activity in ageing and cancer. Mol Cell Endocrinol. 2005; 240(1-2): 11-22
|
|
|
|
|
|
18) Kyo S, Takakura M, Kanaya T, et al. Estrogen activates telomerase. Cancer Res. 1999; 59: 5917-21
|
|
|
|
|
|
19) Misiti S, Nanni S, Fontemaggi G, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol. 2000; 20: 3764-71
|
|
|
|
|
|
20) Wang Z, Kyo S, Takakura M, et al. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 2000; 60: 5376-81
|
|
|
|
|
|
21) Soda H, Raymond E, Sharma S, et al. Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro. Prostate. 2000; 43: 161-8
|
|
|
|
|
|
22) Meeker AK, Sommerfeld HJ, Coffey DS. Telomerase is activated in the prostate and seminal vesicles of the castrated rat. Endocrinology. 1996; 137: 5743-6
|
|
|
|
|
|
23) Ravindranath N, Ioffe SL, Marshall GR, et al. Androgen depletion activates telomerase in the prostate of the nonhuman primate, Macaca mulatta. Prostate. 2001; 49: 79-89
|
|
|
|
|